Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 23;39(8):890–901. doi: 10.1200/JCO.20.01170

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

FIG 1. — Protocol flow diagram. *Following closure of the CEP-701 randomly assigned, patients were guided by risk score to either poor risk or nonpoor risk options. **Following closure of the mTOR inhibition random assignment, patients in this group received DA 50mg alone. ***Following closure of the D Clofarabine arm, patients were recommended to receive FLAG-Ida (which was also the case if renal criteria were not met). †Following closure of the high-dose daunorubicin arm, patients were allocated DA60. ADE, Ara-C, daunorubicin, and etoposide; APL, acute promyelocytic leukemia; CBF, core binding factor; DA, daunorubicin and Ara-C; FLAG-Ida, fludarabine, Ara-C, granulocyte colony-stimulating factor, and idarubicin; GO, gemtuzumab ozogamicin; MACE, amsacrine, Ara-C, and etoposide; MidAc, mitoxantrone and Ara-C; mTor, mammalian target of Rapamicin.